[1] |
Carvalho F S, Burgeiro A, Garcia R, et al. Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy[J]. Medicinal Research Reviews, 2014,34:106-135.
pmid: 23494977
|
[2] |
Arif I S, Hooper C L, Greco F, et al. Increasing doxorubicin activity against breast cancer cells using PPARgamma-ligands and by exploiting circadian rhythms[J]. British Journal of Pharmacology, 2013,169:1178-1188.
doi: 10.1111/bph.12202
pmid: 23578093
|
[3] |
Zhao L, Qi Y, Xu L, et al. MicroRNA-140-5p aggravates doxorubicin-induced cardiotoxicity by promoting myocardial oxidative stress via targeting nrf2 and sirt2[J]. Redox Biology, 2018,15:284-296.
doi: 10.1016/j.redox.2017.12.013
pmid: 29304479
|
[4] |
Li S, Wang W, Niu T, et al. Nrf2 deficiency exaggerates doxorubicin-induced cardiotoxicity and cardiac dysfunction[J]. Oxid Med Cell Longev, 2014,2014:748524.
doi: 10.1155/2014/748524
pmid: 24895528
|
[5] |
Steinherz L J, Steinherz P G, Tan C, et al. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients[J]. Pediatric Blood & Cancer, 1995,24(6):352.
|
[6] |
Cappetta D, De Angelis A, Sapio L, et al. Oxidative stress and cellular response to doxorubicin: a common factor in the complex milieu of anthracycline cardiotoxicity[J]. Oxid Med Cell Longev, 2017(16):1521020.
|
[7] |
Fernandez-Chas M, Curtis M J, Niederer S A. Mechanism of doxorubicin cardiotoxicity evaluated by integrating multiple molecular effects into a biophysical model[J]. British Journal of Pharmacology, 2017, DOI: 10.1111/bph.14104.
doi: 10.1111/bph.15186
pmid: 32608017
|
[8] |
Li M S V, De Santis M C, Cimino J, et al. Phosphoinositide 3-kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth[J]. Circulation, 2018, DOI: 10.1161/CIRCULATIONAHA.117.030352.
doi: 10.1161/CIRCULATIONAHA.119.045526
pmid: 32654539
|
[9] |
Yuan Y P, Ma Z G, Zhang X, et al. Ctrp3 protected against doxorubicin-induced cardiac dysfunction, inflammation and cell death via activation of sirt1[J]. Journal of Molecular and Cellular Cardiology, 2018,114:38-47.
doi: 10.1016/j.yjmcc.2017.10.008
pmid: 29061338
|
[10] |
Tony H, Yu K, Qiu T Z. MicroRNA-208a silencing attenuates doxorubicin induced myocyte apoptosis and cardiac dysfunction[J]. Oxid Med Cell Longev, 2015(17):597032.
|
[11] |
Tao L, Shen S, Fu S, et al. Traditional Chinese medication Qiliqiangxin attenuates cardiac remodeling after acute myocardial infarction in mice[J]. Scientific Reports, 2015, DOI: 10.1038/srep08374.
doi: 10.1038/s41598-020-68334-2
pmid: 32665664
|
[12] |
Lin S, Wu X, Tao L, et al. The metabolic effects of traditional Chinese medication Qiliqiangxin on h9c2 cardiomyocytes[J]. Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology, 2015,37:2246-2256.
|
[13] |
Zhang J, Wei C, Wang H, et al. Protective effect of Qiliqiangxin capsule on energy metabolism and myocardial mitochondria in pressure overload heart failure rats[J]. Evidence-Based Complementary and Alternative Medicine, 2013,2013:378298.
doi: 10.1155/2013/378298
pmid: 24078824
|
[14] |
Yarana C, Carroll D, Chen J, et al. Extracellular vesicles released by cardiomyocytes in a doxorubicin-induced cardiac injury mouse model contain protein biomarkers of early cardiac injury[J]. Clinical Cancer Research, 2017, DOI: 10.1158/1078-0432.CCR-17-2046.
doi: 10.1158/1078-0432.CCR-20-1828
pmid: 32611629
|
[15] |
Khiati S, Dalla Rosa I, Sourbier C, et al. Mitochondrial topoisomerase 1 (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity[J]. Clinical Cancer Research, 2014,20:4873-4881.
doi: 10.1158/1078-0432.CCR-13-3373
pmid: 24714774
|